Promising new agents in the treatment of non-small cell lung cancer

Cancer Chemother Pharmacol. 1996;37(5):385-93. doi: 10.1007/s002800050402.

Abstract

A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

Publication types

  • Review

MeSH terms

  • Aminopterin / analogs & derivatives
  • Aminopterin / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Clinical Trials as Topic
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Docetaxel
  • Humans
  • Lung Neoplasms / drug therapy*
  • Paclitaxel / analogs & derivatives
  • Paclitaxel / therapeutic use
  • Taxoids*
  • Vinblastine / analogs & derivatives
  • Vinblastine / therapeutic use
  • Vinorelbine

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Vinblastine
  • gemcitabine
  • edatrexate
  • Aminopterin
  • Paclitaxel
  • Vinorelbine
  • Camptothecin